Cargando…
Reinitiation and Subsequent Discontinuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers among New and Prevalent Users Aged 65 Years or More with Peripheral Arterial Disease
Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-receptor blockers (ARBs) are recommended in the treatment of arterial hypertension in patients with peripheral arterial disease (PAD). The aims of our study were: (a) to analyse the extent of reinitiation and subsequent discontinuation...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953445/ https://www.ncbi.nlm.nih.gov/pubmed/36830904 http://dx.doi.org/10.3390/biomedicines11020368 |
_version_ | 1784893879566204928 |
---|---|
author | Wawruch, Martin Murin, Jan Tesar, Tomas Petrova, Miriam Paduchova, Martina Celovska, Denisa Havelkova, Beata Trnka, Michal Masarykova, Lucia Alfian, Sofa D. Aarnio, Emma |
author_facet | Wawruch, Martin Murin, Jan Tesar, Tomas Petrova, Miriam Paduchova, Martina Celovska, Denisa Havelkova, Beata Trnka, Michal Masarykova, Lucia Alfian, Sofa D. Aarnio, Emma |
author_sort | Wawruch, Martin |
collection | PubMed |
description | Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-receptor blockers (ARBs) are recommended in the treatment of arterial hypertension in patients with peripheral arterial disease (PAD). The aims of our study were: (a) to analyse the extent of reinitiation and subsequent discontinuation in older hypertensive PAD patients non-persistent with ACEIs/ARBs; (b) to determine patient and medication factors associated with reinitiation and subsequent discontinuation; and (c) to compare these factors between prevalent and new users. The analysis of reinitiation was performed on a sample of 1642 non-persistent patients aged ≥65 years with PAD newly diagnosed in 2012. Patients reinitiating ACEIs/ARBs were used for the analysis of subsequent discontinuation identified according to the treatment gap period of at least 6 months without any prescription of ACEI/ARB. In the group of non-persistent patients, 875 (53.3%) patients reinitiated ACEIs/ARBs during a follow-up (24.8 months on average). Within this group, subsequent discontinuation was identified in 414 (47.3%) patients. Being a new user was associated with subsequent discontinuation, but not with reinitiation. Myocardial infarction during non-persistence and after reinitiation was associated with reinitiation and lower likelihood of subsequent discontinuation, respectively. Being a prevalent or a new user is associated with the use of medication also after initial discontinuation. |
format | Online Article Text |
id | pubmed-9953445 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99534452023-02-25 Reinitiation and Subsequent Discontinuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers among New and Prevalent Users Aged 65 Years or More with Peripheral Arterial Disease Wawruch, Martin Murin, Jan Tesar, Tomas Petrova, Miriam Paduchova, Martina Celovska, Denisa Havelkova, Beata Trnka, Michal Masarykova, Lucia Alfian, Sofa D. Aarnio, Emma Biomedicines Article Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-receptor blockers (ARBs) are recommended in the treatment of arterial hypertension in patients with peripheral arterial disease (PAD). The aims of our study were: (a) to analyse the extent of reinitiation and subsequent discontinuation in older hypertensive PAD patients non-persistent with ACEIs/ARBs; (b) to determine patient and medication factors associated with reinitiation and subsequent discontinuation; and (c) to compare these factors between prevalent and new users. The analysis of reinitiation was performed on a sample of 1642 non-persistent patients aged ≥65 years with PAD newly diagnosed in 2012. Patients reinitiating ACEIs/ARBs were used for the analysis of subsequent discontinuation identified according to the treatment gap period of at least 6 months without any prescription of ACEI/ARB. In the group of non-persistent patients, 875 (53.3%) patients reinitiated ACEIs/ARBs during a follow-up (24.8 months on average). Within this group, subsequent discontinuation was identified in 414 (47.3%) patients. Being a new user was associated with subsequent discontinuation, but not with reinitiation. Myocardial infarction during non-persistence and after reinitiation was associated with reinitiation and lower likelihood of subsequent discontinuation, respectively. Being a prevalent or a new user is associated with the use of medication also after initial discontinuation. MDPI 2023-01-26 /pmc/articles/PMC9953445/ /pubmed/36830904 http://dx.doi.org/10.3390/biomedicines11020368 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wawruch, Martin Murin, Jan Tesar, Tomas Petrova, Miriam Paduchova, Martina Celovska, Denisa Havelkova, Beata Trnka, Michal Masarykova, Lucia Alfian, Sofa D. Aarnio, Emma Reinitiation and Subsequent Discontinuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers among New and Prevalent Users Aged 65 Years or More with Peripheral Arterial Disease |
title | Reinitiation and Subsequent Discontinuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers among New and Prevalent Users Aged 65 Years or More with Peripheral Arterial Disease |
title_full | Reinitiation and Subsequent Discontinuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers among New and Prevalent Users Aged 65 Years or More with Peripheral Arterial Disease |
title_fullStr | Reinitiation and Subsequent Discontinuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers among New and Prevalent Users Aged 65 Years or More with Peripheral Arterial Disease |
title_full_unstemmed | Reinitiation and Subsequent Discontinuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers among New and Prevalent Users Aged 65 Years or More with Peripheral Arterial Disease |
title_short | Reinitiation and Subsequent Discontinuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers among New and Prevalent Users Aged 65 Years or More with Peripheral Arterial Disease |
title_sort | reinitiation and subsequent discontinuation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among new and prevalent users aged 65 years or more with peripheral arterial disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953445/ https://www.ncbi.nlm.nih.gov/pubmed/36830904 http://dx.doi.org/10.3390/biomedicines11020368 |
work_keys_str_mv | AT wawruchmartin reinitiationandsubsequentdiscontinuationofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersamongnewandprevalentusersaged65yearsormorewithperipheralarterialdisease AT murinjan reinitiationandsubsequentdiscontinuationofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersamongnewandprevalentusersaged65yearsormorewithperipheralarterialdisease AT tesartomas reinitiationandsubsequentdiscontinuationofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersamongnewandprevalentusersaged65yearsormorewithperipheralarterialdisease AT petrovamiriam reinitiationandsubsequentdiscontinuationofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersamongnewandprevalentusersaged65yearsormorewithperipheralarterialdisease AT paduchovamartina reinitiationandsubsequentdiscontinuationofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersamongnewandprevalentusersaged65yearsormorewithperipheralarterialdisease AT celovskadenisa reinitiationandsubsequentdiscontinuationofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersamongnewandprevalentusersaged65yearsormorewithperipheralarterialdisease AT havelkovabeata reinitiationandsubsequentdiscontinuationofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersamongnewandprevalentusersaged65yearsormorewithperipheralarterialdisease AT trnkamichal reinitiationandsubsequentdiscontinuationofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersamongnewandprevalentusersaged65yearsormorewithperipheralarterialdisease AT masarykovalucia reinitiationandsubsequentdiscontinuationofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersamongnewandprevalentusersaged65yearsormorewithperipheralarterialdisease AT alfiansofad reinitiationandsubsequentdiscontinuationofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersamongnewandprevalentusersaged65yearsormorewithperipheralarterialdisease AT aarnioemma reinitiationandsubsequentdiscontinuationofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersamongnewandprevalentusersaged65yearsormorewithperipheralarterialdisease |